Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/29/2011

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5.

ACC:  Ernest N. Morial Convention Center (Expo Hall), New Orleans, LA.  Sunday, April 3:  Poster PresentationAbstract: 286Presenter: Jorge Plutzky, MD, Director, Vascular Disease Prevention Program, Brigham and Women's Hospital, Boston, MATitle: "Weight Loss, Blood Pressure, Pulse and Circadian Patterns with Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy for Obesity"Time: 10:00 – 11:15 a.m. CDTLocation: Hall FSession Title: Risk Reduction and Rehabilitation:  Role of Exercise IIAbout Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Corporate Realignment
2. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
3. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
4. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
5. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
6. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
7. Northwest Biotherapeutics Addresses Recent Market Activity
8. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
9. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
10. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
11. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 ReportsnReports.com adds 2016 ... focus on US, EU, China ... the healthcare business intelligence collection of its growing ... report on the Flow Cytometry market spread across ... 282 tables and figures is now available at ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business ... first multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The ... leadership team,” said John Younger, founder of Accolo. “We are growing and his ...
(Date:4/26/2016)... ... April 26, 2016 , ... uBiome, the leading microbial genomics company, welcomes ... company’s Advisory Board. Prior to co-founding Plum in 2007, Neil Grimmer was Vice President ... , A renowned, innovative designer of ideas, products, and brands, Grimmer has been at ...
(Date:4/26/2016)... ... April 26, 2016 , ... Global ... conduct scientific research on highly manipulated stem cells and culture expansion, and cryopreservation ... increase its participation in scientific research and development of new stem cell protocols ...
Breaking Biology Technology:
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
(Date:3/3/2016)... and DE SOTO, Kansas ... U.S.-based Stroke Detection Plus® to offer Oncimmune,s Early ... assessment and early detection of lung cancer ... employers, unions and individuals. --> Early CDT®-Lung ... and individuals. --> Oncimmune, a leader in ...
(Date:3/1/2016)... , March 1, 2016 ... the addition of the  "Global Biometric ...  report to their offering. --> ... addition of the  "Global Biometric Access ... to their offering. --> ...
Breaking Biology News(10 mins):